Qiagen (QGEN) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View QGEN analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price objectives for Qiagen's stock. Their QGEN share price forecasts range from $50.00 to $60.00. On average, they expect the company's stock price to reach $54.87 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.

Qiagen's stock was trading at $49.87 at the beginning of the year. Since then, QGEN shares have decreased by 9.4% and is now trading at $45.16.
View the best growth stocks for 2023 here.

Qiagen saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 3,130,000 shares, a decline of 20.6% from the April 15th total of 3,940,000 shares. Based on an average daily volume of 779,200 shares, the days-to-cover ratio is presently 4.0 days. Currently, 1.4% of the shares of the stock are sold short.
View Qiagen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our QGEN earnings forecast.

Qiagen (NYSE:QGEN) posted its quarterly earnings data on Wednesday, May, 3rd. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.04. The business had revenue of $485.40 million for the quarter, compared to the consensus estimate of $478.23 million. Qiagen had a trailing twelve-month return on equity of 14.08% and a net margin of 17.66%. The firm's revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.80 EPS.

ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Newday Ocean Health ETF (AHOY), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and WisdomTree BioRevolution Fund (WDNA).

Qiagen updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of $2.10- for the period, compared to the consensus earnings per share estimate of $2.10. The company issued revenue guidance of $2.05B-, compared to the consensus revenue estimate of $2.06 billion.

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.36%), FIL Ltd (1.35%), DekaBank Deutsche Girozentrale (1.27%), Perpetual Ltd (1.23%), Arrowstreet Capital Limited Partnership (1.22%) and Wellington Management Group LLP (1.21%).

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QGEN stock can currently be purchased for approximately $45.16.

Qiagen (NYSE:QGEN) has a market capitalization of $10.28 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.54 on an earnings per share basis.

The company employs 6,178 workers across the globe.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.